Where are we for disease modifying therapies and Parkinson's? Why not take some lessons from multiple sclerosis? Fantastic paper by Lorraine Kalia and colleagues in @Nature Reviews Neurology. Can you say MRI? Key Points: - Guess what? ~18 disease-modifying therapies or DMTs for relapsing multiple sclerosis (MS). - One now for primary progressive MS. - None for Parkinson's! - MRI has been a game changer for MS for both diagnosis and measuring outcome. - Reliable outcome measures for progressive MS (which still needs DMT's) and PD will be top priorities. - Animal models and dish based models will be critical as well as of course human trials. - Imaging and other modalities to understand early stages are critical. - Subtyping is hard in both MS and PD. - MS and PD have many different forms/presentations and understanding who to apply which therapy will be important. My take: Love the perspective of learning from another disease. I think it is important in Parkinson's that we learn from MS. Reflecting on how important using MRI has been for MS I beleive is an important lesson in the story. Reading this article gives me inspiration that we are on the right track in Parkinson's. It also gives me hope for those suffering from more progressive forms of MS; help is on the way. nature.com/articles/s41582-0… #Parkinson #multiplesclerosis #MS